Delivery Order SPE2DB24D1205-SPE2DB25FCZVB
- Not listed
- The Defense Logistics Agency awarded a $13,333.53 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune conditions, and this delivery order fulfills immediate pharmaceutical supply...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a delivery order valued at $1,482.94 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on August 12, 2025, with completion targeted for August 13, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic immunosuppressant medication commonly prescribed for rheumatoid arthritis,...
- The Defense Logistics Agency awarded a delivery order valued at $20,192.93 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order represents a non-competitive award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used immunosuppressant medication used to treat autoimmune conditions including rheumatoid...
- The Defense Logistics Agency awarded a $2,416.05 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 29, 2025. This non-competitive delivery order was placed against AmerisourceBergen's broader pharmaceutical supply contract vehicle and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic medication for treating autoimmune...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL medication. This is a firm fixed-price delivery order valued at $33,364.14, with an ultimate completion date of July 22, 2025. The award carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order valued at $3,398.85 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a leading pharmaceutical product used in the treatment of autoimmune and inflammatory...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,192.80 for HUMIRA Pen 40 mg/0.8 mL on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside, firm fixed price delivery order was issued under a competitive procurement process and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication commonly prescribed for rheumatologic...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZVBDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $19,905.32 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. HUMIRA is a widely used biologic pharmaceutical for treating autoimmune and inflammatory conditions including rheumatoid arthritis, psoriasis, and Crohn's disease. This delivery order fulfills federal medical supply requirements across the Department of Defense healthcare system, leveraging AmerisourceBergen's established role as a primary pharmaceutical distributor for military and veteran healthcare programs. The company's comprehensive federal contract portfolio demonstrates its capability to deliver both brand-name specialty medications and generic pharmaceuticals to support the Defense Health Agency and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.9k | 8/22/25 |